RS56129B1 - Analozi agonista receptora opioida mu endomorfina - Google Patents

Analozi agonista receptora opioida mu endomorfina

Info

Publication number
RS56129B1
RS56129B1 RS20170643A RSP20170643A RS56129B1 RS 56129 B1 RS56129 B1 RS 56129B1 RS 20170643 A RS20170643 A RS 20170643A RS P20170643 A RSP20170643 A RS P20170643A RS 56129 B1 RS56129 B1 RS 56129B1
Authority
RS
Serbia
Prior art keywords
nhr
peptide
phe
peptide according
amino acid
Prior art date
Application number
RS20170643A
Other languages
English (en)
Serbian (sr)
Inventor
James E Zadina
Laszlo Hackler
Original Assignee
The Administrators Of The Tulane Educational Fund
United States Dept Of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45441820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS56129(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Administrators Of The Tulane Educational Fund, United States Dept Of Veterans Affairs filed Critical The Administrators Of The Tulane Educational Fund
Publication of RS56129B1 publication Critical patent/RS56129B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
RS20170643A 2010-07-09 2011-07-08 Analozi agonista receptora opioida mu endomorfina RS56129B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36303910P 2010-07-09 2010-07-09
EP11804387.6A EP2590992B1 (en) 2010-07-09 2011-07-08 Mu opioid receptor agonist analogs of the endomorphins
PCT/US2011/043306 WO2012006497A2 (en) 2010-07-09 2011-07-08 Mu opioid receptor agonist analogs of the endomorphins

Publications (1)

Publication Number Publication Date
RS56129B1 true RS56129B1 (sr) 2017-10-31

Family

ID=45441820

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20170643A RS56129B1 (sr) 2010-07-09 2011-07-08 Analozi agonista receptora opioida mu endomorfina

Country Status (13)

Country Link
US (3) US8716436B2 (https=)
EP (2) EP3246333B1 (https=)
JP (2) JP6039553B2 (https=)
CA (1) CA2810170C (https=)
CY (1) CY1120618T1 (https=)
ES (1) ES2632787T3 (https=)
HR (1) HRP20171119T1 (https=)
HU (1) HUE033875T2 (https=)
PL (1) PL2590992T3 (https=)
PT (1) PT2590992T (https=)
RS (1) RS56129B1 (https=)
SI (1) SI2590992T1 (https=)
WO (1) WO2012006497A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110065648A1 (en) * 2009-09-15 2011-03-17 Maione Theodore E Advantageous mu-opiate receptor peptide compounds
US20130178427A1 (en) * 2010-07-09 2013-07-11 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
US20160176930A1 (en) 2010-07-09 2016-06-23 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
WO2014137496A1 (en) * 2013-03-08 2014-09-12 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
JP2021503481A (ja) * 2017-11-17 2021-02-12 サイトジェル ファーマ リミテッド ライアビリティ カンパニー μオピオイド受容体のポリマーアゴニスト
AU2018375087B2 (en) * 2017-11-30 2023-10-05 Cytogel Pharma, Llc Novel analgesic pharmaceutical formulations and uses thereof
US11578100B2 (en) 2018-03-28 2023-02-14 Florida Atlantic University Research Corporation Cyclic peptides, cyclic peptide conjugates and methods of use thereof
RU2687740C1 (ru) * 2018-11-26 2019-05-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Применение пептида Gly-His-Lys-Pro-Gly-Pro для достижения анальгетического эффекта при боли, вызванной температурным раздражением
WO2020227134A1 (en) * 2019-05-03 2020-11-12 The Administrators Of The Tulane Educational Fund Method for treating opioid use disorder
WO2023235232A2 (en) * 2022-05-31 2023-12-07 The Administrators Of The Tulane Educational Fund Glycosylated cyclic endomorphin analogs
CN116120402B (zh) * 2022-11-04 2024-03-15 深圳市维琪科技股份有限公司 一种环肽及其组合物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203496D0 (sv) * 1992-11-20 1992-11-20 Kabi Pharmacia Ab New oligopeptides
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
EP1578786A2 (en) 2002-12-23 2005-09-28 Janssen Pharmaceutica N.V. Heteroaryl peptidomimetics as thrombin receptor antagonists
US7399762B2 (en) * 2005-04-25 2008-07-15 Research Triangle Institute Opioid receptor agonist compounds and their use in treatment of pain
US8809278B2 (en) * 2008-07-11 2014-08-19 University Of Kansas Cyclic tetrapeptides

Also Published As

Publication number Publication date
AU2011274522A1 (en) 2013-02-07
AU2011274522B2 (en) 2016-03-31
EP3246333B1 (en) 2020-10-07
AU2011274522A8 (en) 2016-04-14
EP2590992A2 (en) 2013-05-15
HK1246811A1 (en) 2018-09-14
CY1120618T1 (el) 2019-12-11
US8716436B2 (en) 2014-05-06
JP2013533890A (ja) 2013-08-29
HRP20171119T1 (hr) 2017-10-06
EP2590992A4 (en) 2013-12-18
SI2590992T1 (sl) 2017-11-30
US20150315238A1 (en) 2015-11-05
EP3246333A1 (en) 2017-11-22
ES2632787T3 (es) 2017-09-15
US20120322740A1 (en) 2012-12-20
EP2590992B1 (en) 2017-04-26
HUE033875T2 (en) 2018-01-29
JP6039553B2 (ja) 2016-12-07
JP6279626B2 (ja) 2018-02-14
US20180222940A1 (en) 2018-08-09
WO2012006497A3 (en) 2012-05-24
JP2016084357A (ja) 2016-05-19
WO2012006497A2 (en) 2012-01-12
CA2810170A1 (en) 2012-01-12
PL2590992T3 (pl) 2017-09-29
CA2810170C (en) 2022-01-25
PT2590992T (pt) 2017-07-26

Similar Documents

Publication Publication Date Title
CA2810170C (en) Mu opioid receptor agonist analogs of the endomorphins
US20170369531A1 (en) Mu opioid receptor agonist analogs of the endomorphins
KR101726893B1 (ko) 멜라노코르틴 수용체-특이적 펩티드
SK13082001A3 (sk) Cyklický peptidový analóg a jeho výroba
US20160108090A1 (en) Dynorphin a analogs with bradykinin receptors specificity for modulation of neuropathic pain
US10919939B2 (en) Mu opioid receptor agonist analogs of the endomorphins
WO2009021289A1 (en) Potassium channel inhibitors
AU2011274522B8 (en) Mu opioid receptor agonist analogs of the endomorphins
WO2014137496A1 (en) Mu opioid receptor agonist analogs of the endomorphins
HK1246811B (en) Mu opioid receptor agonist analogs of the endomorphins
HK1180344A (en) Mu opioid receptor agonist analogs of the endomorphins
HK1180344B (en) Mu opioid receptor agonist analogs of the endomorphins
US20250296958A1 (en) Glycosylated cyclic endomorphin analogs
WO2019170919A1 (en) Hybrid mu opioid receptor and neuropeptide ff receptor binding molecules, their methods of preparation and applications in therapeutic treatment
CN120774991A (zh) 一类神经肽ff受体肽类配体及其制备和应用
Joshi Synthesis and biological evaluation of dynorphin analogs and, Caco-2 permeability of opioid macrocyclic tetrapeptides